Stocks in play: MYND Life Sciences

Is pleased to announce it has successfully closed on the previously announced transaction to acquire the right, title and interest in and to the intellectual property rights for the use of psychedelics to treat Dementia from Cava Healthcare Inc., a life sciences company based in Surrey, British Columbia. The acquisition includes all future worldwide rights relating to the use of psychedelics to treat Alzheimer's disease and other dementias. MYND Life Sciences shares C.MYND are trading unchanged at $0.20.